Opdivo
Opdivo 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Melanoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
2 项
已进入 III/IV 期
18 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Biocon Biologics UK PLC
- Fudan University
- Sarah Weiss
- Radboud University Medical Center
- Sanofi
- Vanderbilt-Ingram Cancer Center
- Rutgers, The State University of New Jersey
- Sarcoma Oncology Research Center, LLC
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、荷兰、Chile、Israel、日本、西班牙、Russia、法国、澳大利亚、加拿大、德国
正在招募患者的 Opdivo 研究
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
II 期招募中中国NCT06121700Naltrexone and Propranolol Combined With Immunotherapy
I 期招募中美国NCT05968690Timing of Immunotherapy in Melanoma
不适用招募中荷兰NCT07696715A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
I 期 / II 期招募中美国ChileIsrael日本NCT05584670Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
II 期招募中美国NCT05361720sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
II 期招募中美国NCT05332002Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
II 期招募中美国NCT03886311VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
II 期招募中美国NCT07510334Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
II 期招募中RussiaNCT07130032JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
不适用招募中法国NCT04294771A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
I 期招募中美国澳大利亚加拿大NCT06764771Combination of TATE and PD-1 Inhibitor in Liver Cancer
II 期招募中美国NCT03259867A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
I 期 / II 期招募中美国澳大利亚加拿大德国NCT04895709A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
I 期 / II 期招募中美国NCT06362369Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.
IV 期招募中意大利NCT06903312A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
II 期招募中美国NCT05048212Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
I 期 / II 期招募中英国NCT07718243Towards Cure Via Only Ultra-short ICB in CSCC
II 期招募中荷兰NCT06823479A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
II 期招募中美国NCT07603856Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
I 期 / II 期招募中比利时荷兰西班牙NCT04954599Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
III 期招募中美国加拿大South KoreaNCT05317858TDM for Optimized Outcome in Patients With mRCC.
不适用招募中丹麦NCT04659343Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
II 期招募中美国NCT06745076Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
II 期招募中PolandNCT04875611
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。